English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The case report presents IgA plasma cell myeloma patient treated with chemotherapy, botrezomib, autologous hematopoietic stem cell transplantation, lenalidomide, unrelated donor allogeneic hematopoietic stem cell transplantation and finally pomalidomide (POM). In spite of lack of deep, long-term response after any of the therapies, the combined treatment using all modalities currently available in Poland led to prolonged survival of the patient. Of note, POM employed as sixth-line therapy showed good efficacy and relatively few side effects over a 27-cycle treatment period.

hematologia

Leczenie pomalidomidem chorego na szpiczaka plazmocytowego po przeszczepieniu allogenicznych krwiotwórczych komórek macierzystych od dawcy niespokrewnionego